TGFβ released by cancer cells in TME promotes cancer progression by shaping the architecture of the tumor and by suppressing the antitumor activities of immune cells, thus generating an immunosuppressive environment that prevents or attenuates the efficacy of anticancer immunotherapies. This evidence concerns the gene TGFB1 and neoplasm.